A minimal structural variation can overcome tumour resistance of oxaliplatin: the case of 4,5-dehydrogenation of the cyclohexane ring

A new family of anticancer compounds has been derived from oxaliplatin by inserting a double-bond between carbons 4 and 5 of the 1,2-diaminocyclohexane ring. Testing against a panel of human tumour cell lines including cervical (A431), ovarian (2008), and colon carcinomas (HCT-15 and LoVo), and two...

Descripción completa

Detalles Bibliográficos
Autores principales: Papadia, Paride, Gandin, Valentina, Barbanente, Alessandra, Ruello, Alessandro G., Marzano, Cristina, Micoli, Katia, Hoeschele, James D., Natile, Giovanni, Margiotta, Nicola
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Royal Society of Chemistry 2019
Materias:
Chemistry
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9072990/
https://www.ncbi.nlm.nih.gov/pubmed/35529760
http://dx.doi.org/10.1039/c9ra07760j
_version_ 1784701184991297536
author Papadia, Paride
Gandin, Valentina
Barbanente, Alessandra
Ruello, Alessandro G.
Marzano, Cristina
Micoli, Katia
Hoeschele, James D.
Natile, Giovanni
Margiotta, Nicola
author_facet Papadia, Paride
Gandin, Valentina
Barbanente, Alessandra
Ruello, Alessandro G.
Marzano, Cristina
Micoli, Katia
Hoeschele, James D.
Natile, Giovanni
Margiotta, Nicola
author_sort Papadia, Paride
collection PubMed
description A new family of anticancer compounds has been derived from oxaliplatin by inserting a double-bond between carbons 4 and 5 of the 1,2-diaminocyclohexane ring. Testing against a panel of human tumour cell lines including cervical (A431), ovarian (2008), and colon carcinomas (HCT-15 and LoVo), and two oxaliplatin-resistant clones (LoVo OXP and LoVo MDR) has shown that the new compounds have, in general, equal if not better cytotoxic activity and are able to overcome the oxaliplatin-resistance. Moreover, the oxalato derivative induced lipid droplets increase in LoVo OXP cells thus suggesting the involvement of metabolism stress in its mechanism of action.
format Online
Article
Text
id pubmed-9072990
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher The Royal Society of Chemistry
record_format MEDLINE/PubMed
spelling pubmed-90729902022-05-06 A minimal structural variation can overcome tumour resistance of oxaliplatin: the case of 4,5-dehydrogenation of the cyclohexane ring Papadia, Paride Gandin, Valentina Barbanente, Alessandra Ruello, Alessandro G. Marzano, Cristina Micoli, Katia Hoeschele, James D. Natile, Giovanni Margiotta, Nicola RSC Adv Chemistry A new family of anticancer compounds has been derived from oxaliplatin by inserting a double-bond between carbons 4 and 5 of the 1,2-diaminocyclohexane ring. Testing against a panel of human tumour cell lines including cervical (A431), ovarian (2008), and colon carcinomas (HCT-15 and LoVo), and two oxaliplatin-resistant clones (LoVo OXP and LoVo MDR) has shown that the new compounds have, in general, equal if not better cytotoxic activity and are able to overcome the oxaliplatin-resistance. Moreover, the oxalato derivative induced lipid droplets increase in LoVo OXP cells thus suggesting the involvement of metabolism stress in its mechanism of action. The Royal Society of Chemistry 2019-10-11 /pmc/articles/PMC9072990/ /pubmed/35529760 http://dx.doi.org/10.1039/c9ra07760j Text en This journal is © The Royal Society of Chemistry https://creativecommons.org/licenses/by-nc/3.0/
spellingShingle Chemistry
Papadia, Paride
Gandin, Valentina
Barbanente, Alessandra
Ruello, Alessandro G.
Marzano, Cristina
Micoli, Katia
Hoeschele, James D.
Natile, Giovanni
Margiotta, Nicola
A minimal structural variation can overcome tumour resistance of oxaliplatin: the case of 4,5-dehydrogenation of the cyclohexane ring
title A minimal structural variation can overcome tumour resistance of oxaliplatin: the case of 4,5-dehydrogenation of the cyclohexane ring
title_full A minimal structural variation can overcome tumour resistance of oxaliplatin: the case of 4,5-dehydrogenation of the cyclohexane ring
title_fullStr A minimal structural variation can overcome tumour resistance of oxaliplatin: the case of 4,5-dehydrogenation of the cyclohexane ring
title_full_unstemmed A minimal structural variation can overcome tumour resistance of oxaliplatin: the case of 4,5-dehydrogenation of the cyclohexane ring
title_short A minimal structural variation can overcome tumour resistance of oxaliplatin: the case of 4,5-dehydrogenation of the cyclohexane ring
title_sort minimal structural variation can overcome tumour resistance of oxaliplatin: the case of 4,5-dehydrogenation of the cyclohexane ring
topic Chemistry
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9072990/
https://www.ncbi.nlm.nih.gov/pubmed/35529760
http://dx.doi.org/10.1039/c9ra07760j
work_keys_str_mv AT papadiaparide aminimalstructuralvariationcanovercometumourresistanceofoxaliplatinthecaseof45dehydrogenationofthecyclohexanering
AT gandinvalentina aminimalstructuralvariationcanovercometumourresistanceofoxaliplatinthecaseof45dehydrogenationofthecyclohexanering
AT barbanentealessandra aminimalstructuralvariationcanovercometumourresistanceofoxaliplatinthecaseof45dehydrogenationofthecyclohexanering
AT ruelloalessandrog aminimalstructuralvariationcanovercometumourresistanceofoxaliplatinthecaseof45dehydrogenationofthecyclohexanering
AT marzanocristina aminimalstructuralvariationcanovercometumourresistanceofoxaliplatinthecaseof45dehydrogenationofthecyclohexanering
AT micolikatia aminimalstructuralvariationcanovercometumourresistanceofoxaliplatinthecaseof45dehydrogenationofthecyclohexanering
AT hoeschelejamesd aminimalstructuralvariationcanovercometumourresistanceofoxaliplatinthecaseof45dehydrogenationofthecyclohexanering
AT natilegiovanni aminimalstructuralvariationcanovercometumourresistanceofoxaliplatinthecaseof45dehydrogenationofthecyclohexanering
AT margiottanicola aminimalstructuralvariationcanovercometumourresistanceofoxaliplatinthecaseof45dehydrogenationofthecyclohexanering
AT papadiaparide minimalstructuralvariationcanovercometumourresistanceofoxaliplatinthecaseof45dehydrogenationofthecyclohexanering
AT gandinvalentina minimalstructuralvariationcanovercometumourresistanceofoxaliplatinthecaseof45dehydrogenationofthecyclohexanering
AT barbanentealessandra minimalstructuralvariationcanovercometumourresistanceofoxaliplatinthecaseof45dehydrogenationofthecyclohexanering
AT ruelloalessandrog minimalstructuralvariationcanovercometumourresistanceofoxaliplatinthecaseof45dehydrogenationofthecyclohexanering
AT marzanocristina minimalstructuralvariationcanovercometumourresistanceofoxaliplatinthecaseof45dehydrogenationofthecyclohexanering
AT micolikatia minimalstructuralvariationcanovercometumourresistanceofoxaliplatinthecaseof45dehydrogenationofthecyclohexanering
AT hoeschelejamesd minimalstructuralvariationcanovercometumourresistanceofoxaliplatinthecaseof45dehydrogenationofthecyclohexanering
AT natilegiovanni minimalstructuralvariationcanovercometumourresistanceofoxaliplatinthecaseof45dehydrogenationofthecyclohexanering
AT margiottanicola minimalstructuralvariationcanovercometumourresistanceofoxaliplatinthecaseof45dehydrogenationofthecyclohexanering

Ejemplares similares